Topical preservative-free ophthalmic treatments: an unmet clinical need

References

• Souto EB, Dias-Ferreira J, Lopez-Machado A, et al. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents. Pharmaceutics. 2019 Sep 6;11(9):460. .
   Web of Science ®Google Scholar
• Wilson LA. To preserve or not to preserve, is that the question? Br J Ophthalmol. 1996 Jul;80(7):583–584.
   PubMed Web of Science ®Google Scholar
• Kim MS, Choi CY, Kim JM, et al. Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br J Ophthalmol. 2008 Nov;92(11):1518–1521.
   PubMed Web of Science ®Google Scholar
• Tu EY. Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. Saudi J Ophthalmol. 2014;28(3):182–187.
   PubMedGoogle Scholar
• Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002 May;53(3):263–280. .
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010 Jul;29(4):312–334. .
   PubMed Web of Science ®Google Scholar
• Agency EM. Emea/622721/2009 2009 2020 May 27]. Available from: https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-antimicrobial-preservatives-ophthalmic-preparations-human-use_en.pdf
   Google Scholar
• Kaur IP, Lal S, Rana C, et al. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28(3):93–103.
   PubMed Web of Science ®Google Scholar
• Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9(3–4):361–375.
   PubMedGoogle Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives.Expert Rev Ophthalmol. 2009 [2009 02 01];4(1):59–64.
   Google Scholar
• Takahashi N. Cytotoxicity of mercurial preservatives in cell culture. Ophthalmic Res. 1982;14(1):63–69.
   PubMed Web of Science ®Google Scholar
• Young TL, Higginbotham EJ, Zou XL, et al. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990 Nov;97(11):1423–1427.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000 Jan-Feb;32(1):3–8.
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000 Feb;20(2):85–94.
   PubMed Web of Science ®Google Scholar
• Debbasch C, Pisella PJ, De Saint Jean M, et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2525–2533.
   PubMed Web of Science ®Google Scholar
• Turacli E, Budak K, Kaur A, et al. The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol. 1997;21(1):27–33.
   PubMed Web of Science ®Google Scholar
• Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc U K. 1985;104(Pt 4)):402–409.
   PubMedGoogle Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001 Sep-Oct;18(5):205–215.
   PubMed Web of Science ®Google Scholar
• Gasset AR. Benzalkonium chloride toxicity to the human cornea. Am J Ophthalmol. 1977 Aug;84(2):169–171.
   PubMed Web of Science ®Google Scholar
• Ubels JL, McCartney MD, Lantz WK, et al. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol. 1995 Mar;113(3):371–378.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis H, Cheong M, Sandeman S, et al. Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery. Br J Ophthalmol. 2002 Mar;86(3):299–305.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003 Sep;29(9):1800–1810.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001 Mar;119(3):387–394.
   PubMedGoogle Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013 Dec;22(9):730–735.
   PubMed Web of Science ®Google Scholar
• Moon J, Ko JH, Yoon CH, et al. Effects of 20% human serum on corneal epithelial toxicity induced by benzalkonium chloride: in vitro and clinical studies. Cornea. 2018 May;37(5):617–623.
   PubMed Web of Science ®Google Scholar
• Okahara A, Kawazu K. Local toxicity of benzalkonium chloride in ophthalmic solutions following repeated applications. J Toxicol Sci. 2013;38(4):531–537.
   PubMed Web of Science ®Google Scholar
• Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018 Nov;102(11):1497–1503. .
   PubMedGoogle Scholar
• Lemij HG, Hoevenaars JG, van der Windt C, et al. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785–793.
   PubMed Web of Science ®Google Scholar
• Meloni M, Balzaretti S, Ceriotti L. Medical devices biocompatibility assessment on HCE: evidences of delayed cytotoxicity of preserved compared to preservative free eye drops. Regul Toxicol Pharmacol. 2019 Aug;106:81–89.
   PubMed Web of Science ®Google Scholar
• Meloni M, Pauly A, Servi BD, et al. Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicol In Vitro. 2010 Feb;24(1):276–285.
   PubMed Web of Science ®Google Scholar
• Malet F, Karsenti D, Pouliquen P. Preservative-free ocular hydrating agents in symptomatic contact lens wearers: saline versus PVP solution. Eye Contact Lens. 2003 Jan;29(1):38–43.
   PubMedGoogle Scholar
• Teping C, Wiedemann B. The COMOD system. A preservative-free multidose container for eyedrops. Klin Monbl Augenheilkd. 1994 Oct;205(4):210–217.
   PubMed Web of Science ®Google Scholar
• Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005 Oct;5(5):459–463.
   PubMed Web of Science ®Google Scholar
• Asbell PA. Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Curr Med Res Opin. 2006 Nov;22(11):2149–2157.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;Dec;12(6):486–490.
   PubMed Web of Science ®Google Scholar
• Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998 Jan;82(1):39–42.
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007 May-Jun;17(3):341–349.
   PubMed Web of Science ®Google Scholar
• Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs. 2007;9(2):71–79.
   PubMedGoogle Scholar
• Chamard C, Larrieu S, Baudouin C, et al. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. In: A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmol; 2020 Nov; 98(7):e876–e881.
   Google Scholar
• Gilissen L, De Decker L, Hulshagen T, et al. Allergic contact dermatitis caused by topical ophthalmic medications: keep an eye on it! Contact Dermatitis. 2019 May;80(5):291–297.
   Google Scholar
• Maca SM, Amon M, Findl O, et al. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. Am J Ophthalmol. 2010 May;149(5):777–784.
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Nichamin LD, Hardten DR, et al. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol. 2011 Mar;151(3):420–6 e1.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim HK, Kim JM, et al. Comparison of contamination rates between preserved and preservative-free fluoroquinolone eyedrops. Graefes Arch Clin Exp Ophthalmol. 2013 Mar;251(3):817–824.
   PubMed Web of Science ®Google Scholar
• Birkhoff M. Delivering on the growing need for topical preservative-free ophthalmic treatments. ONdrug Delivery Mag. 2020 Jan;(104):8–12.
   Google Scholar
• Uusitalo H, Pillunat LE, Ropo A, et al. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010 Feb;88(1):12–19.
   PubMed Web of Science ®Google Scholar
• Day DG, Walters TR, Schwartz GF, et al. Bimatoprost. 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013 Aug;97(8):989–993.
   PubMed Web of Science ®Google Scholar
• Parkkari M, Latvala T, Ropo A. Handling test of eye drop dispenser–comparison of unit-dose pipettes with conventional eye drop bottles. J Ocul Pharmacol Ther. 2010 Jun;26(3):273–276.
   PubMed Web of Science ®Google Scholar
• Marx D, Birkhoff M. New devices for dispensing ophthalmic treatments may be the key to managing the life cycles of established products. Drug Delivery Technol. 2010;10(9):16–21.
   Google Scholar
• Gabisson P, Briat B, Le Foll J, et al. Handiness and acceptability of the new Abak bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study. Ann Pharm Fr. 2011 Jan;69(1):22–29.
   PubMedGoogle Scholar
• Hsu KH, Gupta K, Nayaka H, et al. Multidose preservative free eyedrops by selective removal of benzalkonium chloride from ocular formulations. Pharm Res. 2017 Dec;34(12):2862–2872.
   PubMed Web of Science ®Google Scholar
• Chennell P, Delaborde L, Wasiak M, et al. Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions. Eur J Pharm Sci. 2017 Mar;30(100):230–237.
   Google Scholar
• Davidson Z. Developing an efficient ophthalmic device combination product. ONdrug Delivery Mag. 2020 Jan;(104):16–19.
   Google Scholar
• Kashiwagi K. Wide variation of squeezing force and dispensing time interval among eyedropper bottles. J Ophthalmol. 2019;2019:7250563.
   PubMed Web of Science ®Google Scholar
• Moore DB, Hammer JD, Akhtari R, et al. Squeeze me if you can: variability in force requirements to extract a drop from common glaucoma bottles. J Glaucoma. 2016 Sep;25(9):780–784.
   PubMed Web of Science ®Google Scholar
• Marx D, Bartsch T, Wohnhas R, et al. In: Microbial integrity test for preservative-free multidose eyedroppers or nasal spray pumps. LFI-Gebaüde: Pharmind; 2019.
   Google Scholar
• Efficacy of antimicrobial preservation. 5.1.3. 01/2011:50103 ed.: European pharmacopoeia.
   Google Scholar
• Antimicrobial effectiveness testing <51>: US Pharmacopeia; USP 29 NF 24. [Accessed 2020 Sept 08]. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_c51.html
   Google Scholar
• Santovena-Estevez A, Suarez-Gonzalez J, Vera M, et al. Effectiveness of antimicrobial preservation of extemporaneous diluted simple syrup vehicles for pediatrics. J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):405–409.
   PubMedGoogle Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017 Jul;15(3):276–283.
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017 Jul;15(3):438–510.
   PubMed Web of Science ®Google Scholar
• Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017 Jul;15(3):366–403.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016 Mar;100(3):300–306.
   PubMed Web of Science ®Google Scholar
• Lanzini M, Curcio C, Colabelli-Gisoldi RA, et al. In vivo and impression cytology study on the effect of compatible solutes eye drops on the ocular surface epithelial cell quality in dry eye patients. Mediators Inflamm. 2015;2015:351424.
   PubMed Web of Science ®Google Scholar
• Dogru M, Nakamura M, Shimazaki J, et al. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 2013 Dec;22(12):1581–1601.
   PubMed Web of Science ®Google Scholar
• Lin H, Yiu SC. Dry eye disease: A review of diagnostic approaches and treatments. Saudi J Ophthalmol. 2014 Jul;28(3):173–181.
   PubMedGoogle Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016 Feb;23(2):CD009729.
   Google Scholar
• Wakamatsu TH, Dogru M, Matsumoto Y, et al. Evaluation of lipid oxidative stress status in Sjogren syndrome patients. Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):201–210.
   PubMed Web of Science ®Google Scholar
• Li C, Song Y, Luan S, et al. Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride. PLoS One. 2012;7(3):e33688.
   PubMed Web of Science ®Google Scholar
• Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017 Jul;15(3):511–538.
   PubMed Web of Science ®Google Scholar
• Safarzadeh M, Azizzadeh P, Akbarshahi P. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. J Optom. 2017 Oct - Dec;10(4):258–264.
   PubMedGoogle Scholar
• Chen W, Li Z, Hu J, et al. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS One. 2011;6(10):e26103.
   PubMed Web of Science ®Google Scholar
• Ye J, Wu H, Zhang H, et al. Role of benzalkonium chloride in DNA strand breaks in human corneal epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1681–1687.
   PubMed Web of Science ®Google Scholar
• Ohia SE, Opere CA, Leday AM. Pharmacological consequences of oxidative stress in ocular tissues. Mutat Res. 2005 Nov 11;579(1–2):22–36.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Latkany R. Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye. Clin Ophthalmol. 2011;5:587–591.
   PubMedGoogle Scholar
• Lanz R. Comparison of genaqua®–preserved genteal® in multidose bottles vs preservative–free tears naturale® in single dose units in patients with moderate to severe dry eye. Invest Ophthalmol Vis Sci. 2006;47(13): 259-259.
   Google Scholar
• Pucker ADA. Review of the compatibility of topical artificial tears and rewetting drops with contact lenses. In: Cont lens anterior eye. 2020 Oct;43(5):426–432.
   Google Scholar
• Jee D, Park SH, Kim MS, et al. Antioxidant and inflammatory cytokine in tears of patients with dry eye syndrome treated with preservative-free versus preserved eye drops. Invest Ophthalmol Vis Sci. 2014 Jul 3;55(8):5081–5089. .
   PubMed Web of Science ®Google Scholar
• Noecker R, Miller KV. Benzalkonium chloride in glaucoma medications. Ocul Surf. 2011 Jul;9(3):159–162.
   PubMed Web of Science ®Google Scholar
• Tressler CS, Beatty R, Lemp MA. Preservative use in topical glaucoma medications. Ocul Surf. 2011 Jul;9(3):140–158.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002 Apr;86(4):418–423.
   PubMed Web of Science ®Google Scholar
• Januleviciene I, Derkac I, Grybauskiene L, et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–109.
   PubMedGoogle Scholar
• Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014 Jan;23(1):56–60.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000 May;118(5):615–621.
   PubMedGoogle Scholar
• Trocme S, Hwang LJ, Bean GW, et al. The role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials. Ann Pharmacother. 2010 Dec;44(12):1914–1921.
   PubMed Web of Science ®Google Scholar
• Friedlaender MH, Breshears D, Amoozgar B, et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther. 2006 Nov-Dec;23(6):835–841.
   PubMed Web of Science ®Google Scholar
• Foulks GN. BAK to basics. Ocul Surf. 2011 Jul;9(3):139.
   PubMed Web of Science ®Google Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008 Nov;86(7):716–726.
   PubMed Web of Science ®Google Scholar
• Ayaki M, Iwasawa A, Inoue Y. Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells. Clin Ophthalmol. 2010 Oct;21(4):1217–1222.
   Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010 Jun;29(6):618–621.
   PubMed Web of Science ®Google Scholar
• Agnifili L, Fasanella V, Costagliola C, et al. In vivo confocal microscopy of meibomian glands in glaucoma. Br J Ophthalmol. 2013 Mar;97(3):343–349.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Agnifili L, Fasanella V, et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013 Aug;91(5):e397–405.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Agnifili L, Mastropasqua R, et al. Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Curr Opin Pharmacol. 2013 Feb;13(1):56–64.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Agnifili L, Mastropasqua R, et al. In vivo laser scanning confocal microscopy of the ocular surface in glaucoma. Microsc Microanal. 2014 Jun;20(3):879–894.
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Agnifili L, Fasanella V, et al. Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Invest Ophthalmol Vis Sci. 2015 Mar 5;56(3):2050–2058.
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Agnifili L, Fasanella V, et al. In vivo distribution of corneal epithelial dendritic cells in patients with glaucoma. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5996–6002.
   PubMed Web of Science ®Google Scholar
• Agnifili L, Mastropasqua R, Fasanella V, et al. Meibomian gland features and conjunctival goblet cell density in glaucomatous patients controlled with prostaglandin/timolol fixed combinations: a case control, cross-sectional study. J Glaucoma. 2018 Apr;27(4):364–370.
   PubMed Web of Science ®Google Scholar
• Sezgin Akcay BI, Guney E, Bozkurt TK, et al. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study. J Ocul Pharmacol Ther. 2014 Sep;30(7):548–553.
   PubMed Web of Science ®Google Scholar
• Iester M, Telani S, Frezzotti P, et al. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014 Aug;30(6):476–481.
   PubMed Web of Science ®Google Scholar
• El Ameen A, Vandermeer G, Khanna RK, et al. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2019 Nov;29(6):645–653.
   PubMed Web of Science ®Google Scholar
• Lee SY, Lee K, Park CK, et al. Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. PLoS One. 2019;14(6):e0218886.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Scudeller L, Rolle T, et al. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. Expert Opin Drug Saf. 2015 May;14(5):619–623.
   PubMed Web of Science ®Google Scholar
• Oddone F, Tanga L, Kothy P, et al. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: the visionary study. Adv Ther. 2020 Apr;37(4):1436–1451.
   PubMed Web of Science ®Google Scholar
• Stalmans I, Oddone F, Cordeiro MF, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1151–1158.
   PubMed Web of Science ®Google Scholar
• Kanamoto T, Kiuchi Y, Tanito M, et al. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface. J Ocul Pharmacol Ther. 2015 Apr;31(3):156–164.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Gil Pina R, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014 Jul;98(7):926–931.
   PubMed Web of Science ®Google Scholar
• Aptel F, Choudhry R, Stalmans I. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2016 Aug;32(8):1457–1463.
   PubMed Web of Science ®Google Scholar
• Kitazawa Y, Smith P, Sasaki N, et al. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond). 2011 Sep;25(9):1161–1169.
   PubMed Web of Science ®Google Scholar
• Aptel F, Pfeiffer N, Schmickler S, et al. Noninferiority of preservative-free versus bak-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2019 Jun;28(6):498–506.
   PubMed Web of Science ®Google Scholar
• Zhang X, Vadoothker S, Munir WM, et al. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019 Jan;45(1):11–18.
   PubMed Web of Science ®Google Scholar
• Liang H, Baudouin C, Labbe A, et al. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study. PLoS One. 2012;7(3):e33913.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Blini M, Scudeller L, et al. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naive or treated glaucoma and hypertensive patients versus a control group. J Ocul Pharmacol Ther. 2013 Nov;29(9):821–825.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010 May;88(3):329–336.
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Kaarniranta K, Lorenz K, et al. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019 Apr 2;9(4):e024129.
   PubMed Web of Science ®Google Scholar
• Lopes JF, Hubatsch DA, Amaris P. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. BMC Ophthalmol. 2015 Nov;12(15):166.
   Google Scholar
• Hommer A, Schmidl D, Kromus M, et al. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. Eur J Ophthalmol. 2018 Jul;28(4):385–392.
   PubMed Web of Science ®Google Scholar
• Tokuda N, Kitaoka Y, Matsuzawa A, et al. Changes in ocular surface characteristics after switching from benzalkonium chloride-preserved latanoprost to preservative-free tafluprost or benzalkonium chloride-preserved tafluprost. J Ophthalmol. 2017;2017:3540749.
   PubMed Web of Science ®Google Scholar
• Kestelyn PA, Kestelyn PG, De Bacquer D, et al. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. Int Ophthalmol. 2019 Jan;39(1):105–109.
   PubMed Web of Science ®Google Scholar
• Garcia-Feijoo J, Munoz-Negrete FJ, Hubatsch DA, et al. Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. Clin Ophthalmol. 2016;10:2085–2091.
   PubMed Web of Science ®Google Scholar
• Okumichi H, Kiuchi Y, Baba T, et al. The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study. Clin Ophthalmol. 2017;11:1175–1181.
   PubMed Web of Science ®Google Scholar
• Ranno S, Sacchi M, Brancato C, et al. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients. ScientificWorldJournal. 2012;2012:804730.
   PubMedGoogle Scholar
• Abegao Pinto L, Vandewalle E, Gerlier L, et al. Improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combination. Ophthalmologica. 2014;231(3):166–171.
   PubMed Web of Science ®Google Scholar
• Hedengran A, Steensberg AT, Virgili G, et al. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol. 2020 Nov;104(11):1512–1518..
   Google Scholar
• Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010 Dec;248(12):1757–1764.
   PubMed Web of Science ®Google Scholar
• Sanford M. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension. Clin Drug Investig. 2014 Jul;34(7):521–528.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Boboridis KG, Kapis P, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017 Jan;34(1):221–235.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014 Oct;15(15):2255–2262.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013 Dec;97(12):1510–1515.
   PubMed Web of Science ®Google Scholar
• Misiuk-Hojlo M, Pomorska M, Mulak M, et al. The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol. 2019 Mar;29(2):210–215.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol. 2011 Oct;95(10):1466–1469.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Denoyer A, Desbenoit N, et al. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012 Dec;110:40–63.
   Google Scholar
• Bouchemi M, Roubeix C, Kessal K, et al. Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma. Toxicol In Vitro. 2017 Jun;41:21–29.
   PubMed Web of Science ®Google Scholar
• Chang C, Zhang AQ, Kagan DB, et al. Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. Clin Exp Ophthalmol. 2015 Mar;43(2):164–172.
   PubMed Web of Science ®Google Scholar
• Izzotti A, La Maestra S, Micale RT, et al. Genomic and post-genomic effects of anti-glaucoma drugs preservatives in trabecular meshwork. Mutat Res. 2015 Feb;772:1–9.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17:1806–1813.
   PubMed Web of Science ®Google Scholar
• Nattinen J, Jylha A, Aapola U, et al. Patient stratification in clinical glaucoma trials using the individual tear proteome. Sci Rep. 2018 Aug 13;8(1):12038.
   PubMedGoogle Scholar
• Funke S, Beck S, Lorenz K, et al. Analysis of the effects of preservative-free tafluprost on the tear proteome. Am J Transl Res. 2016;8(10):4025–4039.
   PubMed Web of Science ®Google Scholar
• Martinez-de-la-Casa JM, Perez-Bartolome F, Urcelay E, et al. Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. Ocul Surf. 2017 Oct;15(4):723–729.
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Agnifili L, Structural ML. Molecular tear film changes in glaucoma. Curr Med Chem. 2019;26(22):4225–4240.
   PubMed Web of Science ®Google Scholar
• Murugesan V, Dwivedi R, Saini M, et al. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives. Br J Ophthalmol. 2019 Aug 5;bjophthalmol-2019-314234.
   Google Scholar
• Lorenz K, Wasielica-Poslednik J, Bell K, et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS One. 2017;12(2):e0171636.
   PubMed Web of Science ®Google Scholar
• Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008 Jul;6(3):128–142.
   PubMed Web of Science ®Google Scholar
• Georgoudis P, Sabatino F, Szentmary N, et al. Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment. Ophthalmol Ther. 2019 Mar;8(1):5–17.
   PubMed Web of Science ®Google Scholar
• Kiliç A, Topical GB. 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006 Dec;41(6):693–698.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Bremond-Gignac D, Bortolotti M, et al. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol. 2007 Dec;91(12):1662–1666.
   PubMed Web of Science ®Google Scholar
• Mortemousque B, Bourcier T, Khairallah M, et al. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. J Fr Ophtalmol. 2014 Jan;37(1):1–8.
   PubMed Web of Science ®Google Scholar
• Williams DL. A comparative approach to topical cyclosporine therapy. Eye (Lond). 1997;11(Pt 4)):453–464.
   PubMed Web of Science ®Google Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial.Ophthalmology. 2000 [2000 05 01];107(5):967–974.
   PubMed Web of Science ®Google Scholar
• Rhee MK, Mah FS. Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature. Clin Ophthalmol. 2017;11:1157–1166.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease. Drugs. 2017 Nov;77(17):1909–1916.
   PubMed Web of Science ®Google Scholar
• Boujnah Y, Mouchel R, El-Chehab H, et al. [Prospective, monocentric, uncontrolled study of efficacy, tolerance and adherence of cyclosporin 0.1 % for severe dry eye syndrome]. J Fr Ophtalmol. 2018 Feb;41(2):129–135.
   PubMed Web of Science ®Google Scholar
• Tauber J, Schechter BA, Bacharach J, et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921–1929.
   PubMed Web of Science ®Google Scholar
• Goldberg DF, Malhotra RP, Schechter BA, et al. A phase 3, randomized, double-masked study of otx-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019 [2019 09 01];126(9):1230–1237.
   PubMed Web of Science ®Google Scholar
• Mandal A, Gote V, Pal D, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (cequa(r)) for dry eye disease. Pharm Res. 2019 Jan 7;36(2):36.
   PubMed Web of Science ®Google Scholar
• Hedayatfar A, Hashemi H, Asgari S, et al. Comparison of efficacy and ocular surface toxicity of topical preservative-free methylprednisolone and preserved prednisolone in the treatment of acute anterior uveitis. Cornea. 2014 Apr;33(4):366–372.
   PubMed Web of Science ®Google Scholar
• Rossen J, Amram A, Milani B, et al. Contact Lens-induced Limbal Stem Cell Deficiency. Ocul Surf. 2016 Oct;14(4):419–434.
   PubMed Web of Science ®Google Scholar
• Schwartz GS, Holland EJ. Iatrogenic limbal stem cell deficiency. Cornea. 1998 Jan;17(1):31–37.
   PubMed Web of Science ®Google Scholar
• Kim BY, Riaz KM, Bakhtiari P, et al. Medically reversible limbal stem cell disease: clinical features and management strategies. Ophthalmology. 2014 Oct;121(10):2053–2058.
   PubMed Web of Science ®Google Scholar
• Lake D, Tarn A, Ayliffe W. Deep corneal calcification associated with preservative-free eyedrops and persistent epithelial defects. Cornea. 2008 Apr;27(3):292–296.
   PubMed Web of Science ®Google Scholar
• Yagci A, Bozkurt B, Egrilmez S, et al. Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. Cornea. 2011 May;30(5):571–575.
   PubMed Web of Science ®Google Scholar
• Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018 Sep;66:107–131.
   PubMed Web of Science ®Google Scholar
• Priyadarsini S, Whelchel A, Nicholas S, et al. Diabetic keratopathy: insights and challenges. Surv Ophthalmol. 2020 Sep-Oct;65(5):513–529.
   PubMed Web of Science ®Google Scholar
• Ylinen P, Holmström E, Laine I, et al. Anti-inflammatory medication following cataract surgery: a randomized trial between preservative-free dexamethasone, diclofenac and their combination. Acta Ophthalmol. 2018 Aug;96(5):486–493.
   PubMed Web of Science ®Google Scholar
• Ylinen P, Taipale C, Lindholm JM, et al. Postoperative management in cataract surgery: nepafenac and preservative-free diclofenac compared. Acta Ophthalmol. 2018 Dec;96(8):853–859.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Miyazawa A, Shimura M. A comparison of preservative-free diclofenac and preserved diclofenac eye drops after cataract surgery in patients with diabetic retinopathy. J Ocul Pharmacol Ther. 2012 Jun;28(3):283–289.
   PubMed Web of Science ®Google Scholar
• Jee D, Park M, Lee HJ, et al. Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome. J Cataract Refract Surg. 2015 Apr;41(4):756–763.
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Fasanella V, Agnifili L, et al. Anterior segment optical coherence tomography imaging of conjunctival filtering blebs after glaucoma surgery. Biomed Res Int. 2014;2014:610623.
   PubMed Web of Science ®Google Scholar
• Agnifili L, Fasanella V, Mastropasqua R, et al. In vivo goblet cell density as a potential indicator of glaucoma filtration surgery outcome. Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):2928–2935.
   PubMed Web of Science ®Google Scholar
• Agnifili L, Brescia L, Oddone F, et al. The ocular surface after successful glaucoma filtration surgery: a clinical, in vivo confocal microscopy, and immune-cytology study. Sci Rep. 2019 Aug 5;9(1):11299.
   PubMedGoogle Scholar
• Mastropasqua R, Fasanella V, Brescia L, et al. In vivo confocal imaging of the conjunctiva as a predictive tool for the glaucoma filtration surgery outcome. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):Bio114–bio120.
   PubMed Web of Science ®Google Scholar
• Murdoch I. Post-operative management of trabeculectomy in the first three months. Community Eye Health. 2012;25(79–80):73–75.
   PubMedGoogle Scholar
• Teranishi S, Chikama T, Nishida T. [Effect of preservative-free betamethasone sodium phosphate eyedrops on the development of corneal epithelial disorders after penetrating keratoplasty]. Nippon Ganka Gakkai Zasshi. 2009 Feb;113(2):101–106.
   PubMedGoogle Scholar
• Perry HD, Donnenfeld ED. Issues in the use of preservative-free topicals. Manag Care. 2003;Dec;12(12 Suppl):39–41.
   PubMedGoogle Scholar
• Rahman MQ, Tejwani D, Wilson JA, et al. Microbial contamination of preservative free eye drops in multiple application containers. Br J Ophthalmol. 2006 Feb;90(2):139–141.
   PubMed Web of Science ®Google Scholar
• Oldham GB, Andrews V. Control of microbial contamination in unpreserved eyedrops. Br J Ophthalmol. 1996 Jul;80(7):588–591.
   PubMed Web of Science ®Google Scholar
• Santvliet LV, Sam TLS, Ludwig A, editors. In: Packaging of ophthalmic solutions: influence on stability, sterility, eye drop instillation and patient compliance. Eur J Pharm Biopharm. 1996;42(6):375–384.
   Google Scholar
• Chibret H. [Ophthalmic preservatives and preparations: reality and perspectives]. Ann Pharm Fr. 1997;55(5):228–231.
   PubMedGoogle Scholar
• Waduthantri S, Yong SS, Tan CH, et al. Cost of dry eye treatment in an Asian clinic setting. PLoS One. 2012;7(6):e37711.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother. 2003 Oct;4(10):1775–1788.
   PubMed Web of Science ®Google Scholar
• Popovic M, Chan C, Lattanzio N, et al. Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario. Can J Ophthalmol. 2018 Apr;53(2):173–187.
   PubMed Web of Science ®Google Scholar
• Committee BJF. British National Formulary (BNF). 72. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society; 2016.
   Google Scholar
• Tachkov K, Vassilev A, Kostova S. Modeling the pharmacotherapy cost and outcomes of primary open-angle glaucoma with dry eye. Front Public Health. 2019;7:363.
   PubMed Web of Science ®Google Scholar
• Shahbandeh M Global eye drops and lubricants market revenue 2017-2025 2019 [2020 Sept 22]. Available from: https://www.statista.com/statistics/1046762/eye-drops-and-lubricants-market-revenue-global/#statisticContainer
   Google Scholar
• Mehuys E, Delaey C, Christiaens T, et al. Eye drop technique and patient-reported problems in a real-world population of eye drop users. Eye (Lond). 2020 Aug;34(8):1392–1398.
   Google Scholar
• Loeffler M, Hornblass A. Hazards of unit dose artificial tear preparations. Arch Ophthalmol. 1990 May;108(5):639–640.
   PubMedGoogle Scholar
• Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131–2135.
   PubMedGoogle Scholar
• Bagnis A, Papadia M, Scotto R, et al. Antiglaucoma drugs: the role of preservative-free formulations. Saudi J Ophthalmol. 2011 Oct;25(4):389–394.
   PubMedGoogle Scholar
• Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990 Aug;74(8):477–480.
   PubMed Web of Science ®Google Scholar
• Ribeiro M, Barbosa FT, Ribeiro LEF, et al. Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review. Arq Bras Oftalmol. 2019 Sep 9;82(5):436–445.
   PubMed Web of Science ®Google Scholar
• Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009 May;26(5):1197–1216.
   PubMed Web of Science ®Google Scholar
• Li YJ, Luo LJ, Harroun SG, et al. Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease. Nanoscale. 2019 Mar 21;11(12):5580–5594.
   PubMed Web of Science ®Google Scholar
• Luo LJ, Nguyen DD, Lai JY. Long-acting mucoadhesive thermogels for improving topical treatments of dry eye disease. Mater Sci Eng C Mater Biol Appl. 2020 Oct;115:111095.
   PubMed Web of Science ®Google Scholar
• Luo LJ, Nguyen DD, Lai JY. Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy. Biomaterials. 2020 Jun;243:119961.
   PubMed Web of Science ®Google Scholar
• Lai J-Y, Luo L-J, Nguyen DD. Multifunctional glutathione-dependent hydrogel eye drops with enhanced drug bioavailability for glaucoma therapy. Chem Eng J. 2020;402:126190. 2020 12 15.
   Web of Science ®Google Scholar
• Jian HJ, Wu RS, Lin TY, et al. Super-cationic carbon quantum dots synthesized from spermidine as an eye drop formulation for topical treatment of bacterial keratitis. ACS Nano. 2017 Jul 25;11(7):6703–6716.
   PubMed Web of Science ®Google Scholar